Nano Curcumin Supplementation Reduced The Severity Of Diabetic Sensorimotor Polyneuropathy In Patients With Type 2 Diabetes Mellitus: A Randomized Double-blind Placebo- Controlled Clinical Trial
Notes for this study:
||Toronto Clinical Neuropathy Score. Total. Placebo: before 10.5(1.2), after 9.92(1.3). Curcumin: before 10.8(1.2), after 8.46(1.5)
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 80 participants with type 2 diabetes and diabetic distal symmetric polyneuropathy were assigned to take 80 mg of nanocurcumin (curcumin mixture 72% curcumin, 25% demethoxycurcumin, 3% bisdemethoxycurcumin) or placebo for 8 weeks.
There was a statistically significant reduction in fasting blood sugar and HbA1c levels in the curcumin group compared with placebo, which remained statistically significant after adjustment for the duration of neuropathy, protein intake, and waist circumference. 2-hour postprandial blood sugar was reduced more in the curcumin group this wasn't statistically significant between groups.
The Toronto Clinical Neuropathy Score was used to measure diabetic distal symmetric polyneuropathy severity. There was a statistically significant reduction in total neuropathy score, total reflex score, and temperature in the curcumin group compared with placebo, and which remained statistically significant after adjustment except for the total reflex score. No statistically significant differences were found for total symptom score, foot pain, numbness, weakness, tingling, upper limb symptoms, total sensory score, pinprick, light touch, vibration, position sense, ankle reflexes, or knee reflexes. The authors found that reduction in fasting blood sugar and HbA1c were associated with a reduction in diabetic distal symmetric polyneuropathy.